Skip to Main Content

1.2.13: Develop and implement individualized treatment plans, taking into consideration pharmacoeconomic factors

A newly diagnosed patient with CML receives a script for imatinib 400 mg orally daily. The patient is uninsured. She arrives at your pharmacy asking questions about this medication. What is the best course of action?

(A) Instruct the patient to pay with cash.

(B) Refer the patient back to her physician for an alternative agent.

(C) Offer to contact the pharmaceutical company to discuss a patient assistance program.

(D) Instruct the patient to wait on approval for Medicaid and delay therapy.

The Correct Answer is: C

The best option for this patient is to apply for an industry patient assistance program until she qualifies for Medicaid (C).

Oral TKI therapy is expensive and most patients will not be able to afford it without financial assistance (A). Alternative agents such as dasatinib and nilotinib are more expensive (B). Do not delay therapy (D). Assist the patient in enrolling in a patient assistance program and emphasize medication adherence.

Topic: Leukemia

A newly diagnosed patient with CML receives a script for imatinib 400 mg orally daily. Patient is uninsured and has applied for Medicaid. They arrive at your pharmacy asking questions about this medication. What is the best course of action?

(A) Instruct patient to pay with cash.

(B) Refer them back to their physician for alternative agent.

(C) Offer to contact pharmaceutical company for patient assistance program.

(D) Instruct patient to wait on approval for Medicaid and delay therapy.

The correct answer is (C).

The best option for this patient is to apply for an industry patient assistance program until they qualify for Medicaid.

Choice (A) is incorrect. Oral TKI therapy is expensive and most patients will not be able to afford these without financial assistance.

Choice (B) is incorrect. Alternative agents such as dasatinib and nilotinib are more expensive.

Choice (D) is incorrect. Do not delay therapy. Assist patient in enrolling in patient assistance program and emphasize medication adherence.

RA is a 33-year-old female exhibiting intolerable side effects to her first-generation antipsychotic chlorpromazine. RA was placed on a first-generation due to cost issues. First generation antipsychotics are significantly cheaper than second generation (for example, chlorpromazine costs about $140 per month and Paliperidone costs about $600 per month). RA travels and speaks for a living and states that she does not like being on antipsychotics due to unwanted side effects of ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.